Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ITIL-306 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1a: Dose Escalation | EXPERIMENTAL | Various doses will be tested in participants with EOC, NSCLC and RCC. |
| Phase 1b: Expansion | EXPERIMENTAL | Cohort 1: Participants with epithelial ovarian cancer (EOC) Cohort 2: Participants with non-small cell lung cancer (NSCLC) Cohort 3: Participants with renal cell carcinoma (RCC) |
| Name | Type | Description |
|---|---|---|
| ITIL-306 | BIOLOGICAL | ITIL-306 is a cell therapy product derived from a participant's own TILs and contains a unique molecule designed to increase TIL activity when it encounters FOLR1 on the tumor. A portion of the participant's tumor is surgically removed to make a personalized ITIL-306 product. Once ITIL-306 has been made, the participant is treated with 3 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by 2 days of rest then a single infusion of ITIL-306. |
Key Inclusion Criteria: * Histologically documented advanced (metastatic and/or unresectable) disease as appropriate per cohort. * Phase 1a Dose Escalation: High-grade serous epithelial carcinoma of the ovary, fallopian tube, or peritoneum, adenocarcinoma of the lung, or clear-cell renal cell ca...
ITIL-306 is an investigational monoclonal antibody being developed for the treatment of epithelial ovarian cancer. It is also being studied in other advanced solid tumors, including non-small cell lung cancer and renal cell carcinoma. The drug is currently in Phase 1 clinical development.
ITIL-306 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being investigated for its potential to treat epithelial ovarian cancer and other advanced solid tumors. Its mechanism of action is not publicly detailed.
ITIL-306 is being developed by Instil Bio, Inc., a biopharmaceutical company. Instil Bio is publicly traded on the Nasdaq under the ticker symbol TIL. The company is conducting clinical trials to evaluate the safety and efficacy of ITIL-306 in patients with advanced solid tumors.
ITIL-306 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of ITIL-306 in patients with advanced solid tumors.
ITIL-306 is being evaluated in a Phase 1 clinical trial with the identifier NCT05397093, titled 'ITIL-306 in Advanced Solid Tumors.' The trial is enrolling patients with epithelial ovarian cancer, non-small cell lung cancer, and renal cell carcinoma. The study is being conducted in the United States.
ITIL-306 is a distinct investigational drug developed by Instil Bio. No alternative names for ITIL-306 have been reported. It is a monoclonal antibody being studied for the treatment of advanced solid tumors, including epithelial ovarian cancer.